[go: up one dir, main page]

EE05650B1 - Antikehade radioaktiivse m„rgistamise komplekt ja seostamistest - Google Patents

Antikehade radioaktiivse m„rgistamise komplekt ja seostamistest

Info

Publication number
EE05650B1
EE05650B1 EEP200100465A EEP200100465A EE05650B1 EE 05650 B1 EE05650 B1 EE 05650B1 EE P200100465 A EEP200100465 A EE P200100465A EE P200100465 A EEP200100465 A EE P200100465A EE 05650 B1 EE05650 B1 EE 05650B1
Authority
EE
Estonia
Prior art keywords
antibody
radiolabeling
binding assay
labeling kit
radioactive labeling
Prior art date
Application number
EEP200100465A
Other languages
English (en)
Estonian (et)
Inventor
Chinn Paul
Morena Ronald
Labarre Michael
E. Leonard John
Original Assignee
Idec Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corporation filed Critical Idec Pharmaceuticals Corporation
Publication of EE200100465A publication Critical patent/EE200100465A/xx
Publication of EE05650B1 publication Critical patent/EE05650B1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Packages (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200100465A 1999-03-01 2000-02-29 Antikehade radioaktiivse m„rgistamise komplekt ja seostamistest EE05650B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/259,337 US20020102208A1 (en) 1999-03-01 1999-03-01 Radiolabeling kit and binding assay
PCT/US2000/005061 WO2000052473A2 (en) 1999-03-01 2000-02-29 Radiolabeling kit and binding assay

Publications (2)

Publication Number Publication Date
EE200100465A EE200100465A (et) 2002-10-15
EE05650B1 true EE05650B1 (et) 2013-04-15

Family

ID=22984524

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100465A EE05650B1 (et) 1999-03-01 2000-02-29 Antikehade radioaktiivse m„rgistamise komplekt ja seostamistest

Country Status (35)

Country Link
US (2) US20020102208A1 (xx)
EP (2) EP1192463B1 (xx)
JP (1) JP4704570B2 (xx)
KR (1) KR100729247B1 (xx)
CN (1) CN1235639C (xx)
AT (1) ATE433108T1 (xx)
AU (1) AU776747B2 (xx)
BG (1) BG65690B1 (xx)
BR (2) BRPI0008719B8 (xx)
CA (2) CA2742153C (xx)
CY (2) CY1109335T1 (xx)
CZ (2) CZ303262B6 (xx)
DE (1) DE60042326D1 (xx)
DK (2) DK2112512T3 (xx)
EE (1) EE05650B1 (xx)
ES (2) ES2328100T3 (xx)
HK (1) HK1045730B (xx)
HR (1) HRP20010714B1 (xx)
HU (2) HU230516B1 (xx)
IL (1) IL145109A0 (xx)
ME (1) ME00782B (xx)
MX (1) MXPA01008837A (xx)
MY (1) MY138674A (xx)
NO (2) NO329142B1 (xx)
NZ (2) NZ513788A (xx)
PL (1) PL205780B1 (xx)
PT (2) PT2112512E (xx)
RS (1) RS51778B (xx)
RU (1) RU2251110C2 (xx)
SI (2) SI2112512T1 (xx)
SK (2) SK288096B6 (xx)
TW (1) TWI294969B (xx)
UA (1) UA78484C2 (xx)
WO (1) WO2000052473A2 (xx)
ZA (1) ZA200106943B (xx)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
EP1918305A1 (en) 1999-08-11 2008-05-07 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
JP4202127B2 (ja) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
US20030003097A1 (en) * 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
CA2452288A1 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
DE60323677D1 (de) 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004253924B2 (en) * 2003-06-25 2009-07-30 Peregrine Pharmaceuticals, Inc. Method and apparatus for continuous large-scale radiolabeling of proteins
ATE474599T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
ATE476448T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung
CA2544368C (en) 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
DK1682177T3 (da) 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi
WO2005044305A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
HRP20130852T1 (xx) 2005-05-18 2013-10-25 Novartis Ag Postupci dijagnoze i lijeäśenja bolesti koje imaju autoimunu i/ili upalnu komponentu
ES2434470T3 (es) 2005-07-08 2013-12-16 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
WO2007023408A2 (en) * 2005-08-25 2007-03-01 Koninklijke Philips Electronics N.V. 4d image-based planning methods and apparatus for targeted therapy
EP3095467B1 (en) * 2005-11-23 2020-05-06 Ventana Medical Systems, Inc. Antibody-enzyme conjugate
KR101317235B1 (ko) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
JP5512275B2 (ja) * 2006-11-10 2014-06-04 ラディオプロテクト アルファプトーゼ ウーゲー（ハフツングスベシュレンクト） ウント コー．カーゲー 放射線傷害治療のための三置換グリセロール化合物の使用
CZ300074B6 (cs) * 2006-12-20 2009-01-21 Azacycles S. R. O. Inteligentní trífunkcní makrokonjugáty a farmaceutický nebo diagnostický prostredek s jejich obsahem
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
EP2740744B1 (en) 2007-01-09 2018-03-28 Biogen MA Inc. Sp35 antibodies and uses thereof
MY171841A (en) * 2007-12-21 2019-11-04 Hoffmann La Roche Antibody formulation
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
JP5422649B2 (ja) 2008-07-16 2014-02-19 インスティテュート フォー リサーチ イン バイオメディシン ヒトサイトメガロウイルス中和抗体およびその使用
CN102143974B (zh) 2008-07-16 2015-03-25 生命医学研究学会 人巨细胞病毒中和抗体及其用途
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US9340603B2 (en) 2008-07-25 2016-05-17 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
BRPI0914012B1 (pt) 2008-10-13 2022-02-15 Institute For Research In Biomedicine Composição farmacêutica e uso da composição farmacêutica
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2011092593A2 (en) 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
JP5917418B2 (ja) 2010-03-12 2016-05-11 ジェンザイム・コーポレーションＧｅｎｚｙｍｅ Ｃｏｒｐｏｒａｔｉｏｎ 乳がんを治療するための併用療法
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
ES2652508T3 (es) 2010-08-06 2018-02-02 Genzyme Corporation Composiciones de antagonistas de VEGF y sus usos
EP2603613B1 (en) * 2010-08-13 2015-04-08 RDM Empreendimentos e Participaçöes S.A. Method and composition for reducing the color of sugar
US20140142049A1 (en) 2011-03-11 2014-05-22 Zhiqiang Jia Pegylated apelin and uses thereof
DK3418300T3 (da) 2011-07-18 2020-12-07 Inst Res Biomedicine Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
EP2793949B1 (en) 2011-12-23 2018-08-22 Innate Pharma Enzymatic conjugation of antibodies
AU2013237087B2 (en) 2012-03-20 2017-07-20 Humabs Biomed Sa Antibodies that neutralize RSV, MPV and PVM and uses thereof
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
RU2522203C2 (ru) * 2012-06-26 2014-07-10 Василий Александрович Ишутин Способ контроля стерилизации материалов и изделий
WO2014009426A2 (en) * 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
IL319584A (en) 2013-03-11 2025-05-01 Genzyme Corp Polypeptides with hyperglycosidic bonds
WO2014165216A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
RU2558929C2 (ru) * 2013-08-08 2015-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" (НИИ Кардиологии) СПОСОБ ОПРЕДЕЛЕНИЯ СВЯЗЫВАНИЯ РАДИОФАРМПРЕПАРАТА НА ОСНОВЕ ЦИПРОФЛОКСАЦИНА, МЕЧЕННОГО 99mTc C БАКТЕРИЯМИ
KR20160035077A (ko) 2013-08-13 2016-03-30 사노피 플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도
US11052177B2 (en) 2013-09-06 2021-07-06 The Trustees Of The University Of Pennsylvania Antimicrobial polymer layers
CN113667012B (zh) 2013-10-02 2024-07-12 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
WO2015131153A1 (en) * 2014-02-27 2015-09-03 Board Of Regents, The University Of Texas System Methods and compositions for isolating exosomes
RS64072B1 (sr) 2014-03-19 2023-04-28 Genzyme Corp Mesto-specifični glikoinženjering ciljnih delova
KR102553870B1 (ko) 2014-03-27 2023-07-10 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
US12214038B2 (en) 2014-07-22 2025-02-04 The Trustees Of The University Of Pennsylvania Compositions and methods for cancer immunotherapy
WO2016055950A1 (en) 2014-10-08 2016-04-14 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
US10064952B2 (en) 2014-10-09 2018-09-04 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
CN107428819B (zh) 2014-11-18 2022-03-15 胡默波斯生物医学公司 强力地中和狂犬病毒和其它狂犬病毒属病毒的抗体和其用途
EP3960761A1 (en) 2015-06-01 2022-03-02 MedImmune, LLC Neutralizing anti-influenza binding molecules and uses thereof
HK1256553A1 (zh) 2015-07-30 2019-09-27 The Trustees Of The University Of Pennsylvania 用於检测pgd2对毛发生长抑制的易感性的人dp-2基因的单核苷酸多态性等位基因
WO2017040708A1 (en) 2015-08-31 2017-03-09 Fruition Marketing, Llc Consumer usable device with redeemable member
KR20180042449A (ko) 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
US11421026B2 (en) 2015-09-30 2022-08-23 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
JP2019502715A (ja) 2016-01-13 2019-01-31 メディミューン，エルエルシー Ａ型インフルエンザを治療する方法
WO2018010789A1 (en) * 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
EP3612562A2 (en) 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
CA3061963A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
EP3655036B1 (en) 2017-07-19 2024-09-04 Hoffman Technologies, LLC Compositions for treating stress-related disorders
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
RU2700584C1 (ru) * 2018-12-13 2019-09-18 Общество С Ограниченной Ответственностью "Апто-Фарм" Способ оценки сродства олигонуклеотида
DK3898668T5 (da) 2018-12-19 2024-08-05 Humabs Biomed Sa Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf
CN113939534B (zh) 2019-04-03 2025-02-28 建新公司 具有降低的断裂的抗αβTCR结合多肽
EP4021578A1 (en) 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
US11879004B2 (en) 2020-02-28 2024-01-23 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
EP4164745A1 (en) 2020-06-11 2023-04-19 Vaccinex, Inc. Use of cxcl13 binding molecules to promote peripheral nerve regeneration
EP4284428A1 (en) 2021-01-26 2023-12-06 VIR Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
TW202430561A (zh) 2022-09-30 2024-08-01 法商賽諾菲公司 抗cd28抗體
TW202432574A (zh) 2022-10-25 2024-08-16 比利時商艾伯霖克斯公司 具有增強的效應子功能之糖基工程化Ｆｃ變體多肽
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2025177185A1 (en) * 2024-02-20 2025-08-28 Janssen Biotech, Inc. Materials and methods for biologic affinity analysis
WO2025257408A1 (en) 2024-06-14 2025-12-18 Sanofi Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) * 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) * 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
JPS5982222U (ja) * 1982-11-26 1984-06-02 松井　三郎 眼鏡
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) * 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
CA1266344A (en) * 1986-02-14 1990-02-27 Miki Kurami High molecular compounds having amino groups, and their utilization
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0484989B1 (en) * 1986-09-05 1996-04-24 GANSOW, Otto A. Polysubstituted diethylenetriamine chelates for forming a metal-chelate-protein conjugate
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
WO1992011864A1 (en) * 1991-01-11 1992-07-23 Cryopharm Corporation Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
DE68925904T2 (de) * 1988-05-25 1996-10-31 The United States Of America, Represented By The Secretary, U.S. Department Of Commerce, Springfield, Va. Makrocyclische chelate und verwendungsverfahren
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) * 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
CA2095141A1 (en) 1990-11-05 1992-05-06 Ingegerd Hellstrom Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US5208008A (en) * 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
US5403573A (en) * 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PL174721B1 (pl) * 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5942210A (en) 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay

Also Published As

Publication number Publication date
SI2112512T1 (sl) 2015-02-27
BRPI0017596B1 (pt) 2015-09-01
MXPA01008837A (es) 2002-05-14
AU3505200A (en) 2000-09-21
YU61601A (sh) 2004-07-15
HK1131208A1 (en) 2010-01-15
EP2112512A2 (en) 2009-10-28
DE60042326D1 (de) 2009-07-16
ME00782B (me) 2012-03-20
CZ303262B6 (cs) 2012-07-04
BG65690B1 (bg) 2009-06-30
HUP0202522A3 (en) 2011-03-28
AU776747B2 (en) 2004-09-23
CA2362119A1 (en) 2000-09-08
ES2526723T3 (es) 2015-01-14
IL145109A0 (en) 2002-06-30
DK2112512T3 (en) 2014-12-15
SK287745B6 (sk) 2011-08-04
BRPI0017596A2 (pt) 2011-09-27
HK1045730A1 (en) 2002-12-06
HRP20010714A2 (en) 2003-02-28
PL205780B1 (pl) 2010-05-31
NZ530868A (en) 2005-12-23
ATE433108T1 (de) 2009-06-15
BRPI0008719A (pt) 2001-12-26
NZ513788A (en) 2004-03-26
CA2742153C (en) 2015-04-14
NO329142B1 (no) 2010-08-30
CA2362119C (en) 2012-12-11
HU229627B1 (en) 2014-03-28
US20050169838A1 (en) 2005-08-04
JP2002538179A (ja) 2002-11-12
BRPI0008719B1 (pt) 2015-07-21
PT1192463E (pt) 2009-09-10
EP1192463B1 (en) 2009-06-03
JP4704570B2 (ja) 2011-06-15
NO20100717L (no) 2001-10-31
ZA200106943B (en) 2002-11-22
KR100729247B1 (ko) 2007-06-15
HUP1300275A2 (en) 2002-11-28
WO2000052473A2 (en) 2000-09-08
HRP20010714B1 (hr) 2009-01-31
CN1235639C (zh) 2006-01-11
BG105957A (en) 2002-08-30
BRPI0008719B8 (pt) 2021-07-06
WO2000052473A9 (en) 2001-03-08
HU230516B1 (hu) 2016-10-28
PL352531A1 (en) 2003-08-25
UA78484C2 (en) 2007-04-10
EP2112512A3 (en) 2009-12-16
EE200100465A (et) 2002-10-15
KR20020021772A (ko) 2002-03-22
NO330705B1 (no) 2011-06-20
SK12162001A3 (sk) 2002-12-03
CY1116265T1 (el) 2017-02-08
RU2251110C2 (ru) 2005-04-27
SI1192463T1 (sl) 2009-10-31
RS51778B (sr) 2011-12-31
EP1192463A2 (en) 2002-04-03
DK1192463T3 (da) 2009-10-05
MY138674A (en) 2009-07-31
HUP0202522A2 (hu) 2002-11-28
HK1045730B (zh) 2006-08-18
ES2328100T3 (es) 2009-11-10
PT2112512E (pt) 2015-01-13
NO20014245L (no) 2001-10-31
CY1109335T1 (el) 2014-07-02
TWI294969B (xx) 2008-03-21
CZ20013126A3 (cs) 2002-07-17
NO20014245D0 (no) 2001-08-31
WO2000052473A3 (en) 2002-01-31
CZ306959B6 (cs) 2017-10-11
US20020102208A1 (en) 2002-08-01
US7608241B2 (en) 2009-10-27
SK288096B6 (sk) 2013-07-02
CA2742153A1 (en) 2000-09-08
BRPI0017596B8 (pt) 2023-04-25
EP2112512B1 (en) 2014-11-19
CN1345417A (zh) 2002-04-17

Similar Documents

Publication Publication Date Title
EE05650B1 (et) Antikehade radioaktiivse m„rgistamise komplekt ja seostamistest
BRPI9912227B8 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
GB9824632D0 (en) Biological compounds
ATE322014T1 (de) Krebsnachweisverfahren und reagenzien
DE3766157D1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
NO20005694D0 (no) Spesifikke bindingsmolekyler for scintigrafi, konjugater som inneholder disse og terapeutisk metode for behandling av angiogenese
ATE423220T1 (de) Testverfahren für verbindungen die frühzeitige translations beendigung und nonsense rns decay hemmen
IL140413A0 (en) A complex of an enzyme, a protein and a carrier
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
FI905350A7 (fi) Leimattua streptokokki-vasta-ainetta sisältävä koostumus, testipakkaus ja analyysimenetelmä, jossa sitä käytetään
ATE414904T1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2- glycoprotein-i-komplexes in vivo
ATE208040T1 (de) Immunoassay-reagenzien, testsätze und verfahren
CO4410342A1 (es) Procedimiento para obtener un reactivo que permite cuantifi- car la toxina de un parasito del genero sarcocystis